TY - JOUR
T1 - The hypoglycemia-prevention effect of sensor-augmented pump therapy with predictive low glucose management in Japanese patients with type 1 diabetes mellitus
T2 - a short-term study
AU - Katayama, Akihiro
AU - Tone, Atsuhito
AU - Watanabe, Mayu
AU - Teshigawara, Sanae
AU - Miyamoto, Satoshi
AU - Eguchi, Jun
AU - Nakatsuka, Atsuko
AU - Shikata, Kenichi
AU - Wada, Jun
N1 - Funding Information:
Author Atsuhito T. received lecture fees from Medtronic Japan, Sanofi and Eli Lilly. Author Jun W. received lecture fees from Astellas, Astra Zeneca, Boeringer Ingelheim Japan, Daiichi Sankyo, MSD, Novartis, Tanabe Mitsubishi and Taisho Toyama, and received research funding from Bayer, Baxter, Chugai, Dainippon Sumitomo, Kyowa Hakko Kirin, MSD, Novartis, Novo Nordisk, Ono, Takeda, Tanabe Mitsubishi and Teijin. Other authors declare that they have no conflict of interest associated with this research.
Publisher Copyright:
© 2019, The Japan Diabetes Society.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Aims/introduction: The predictive low glucose management (PLGM) system was introduced in March 2018 in Japan. Although there are some reports demonstrating the benefit of PLGM in preventing hypoglycemia, no data are currently available in Japanese patients with type 1 diabetes mellitus (T1DM). The aim of the present study is to evaluate the effect of PLGM with sensor-augmented pump therapy in the prevention of hypoglycemia in Japanese patients. Materials and methods: We included 16 patients with T1DM who used the MiniMed®640G system after switching from the MiniMed®620G system. We retrospectively analysed the data of the continuous glucose monitoring system in 1 month after switching to MiniMed®640G. Results: The area under the curve (AUC) of hypoglycemia of < 70 mg/dL was lowered from 0.42 ± 0.43 mg/dL day to 0.18 ± 0.18 mg/dL day (P = 0.012). Correspondingly, the duration of severe hypoglycemia (< 54 mg/dL) was reduced significantly from 15.3 ± 21.7 min/day to 4.8 ± 6.9 min/day (P = 0.019). The duration of hypoglycemia was reduced, but the reduction was not significant. Regarding the AUC for hyperglycemia > 180 mg/dL and the duration of hyperglycemia did not change. With the PLGM function, 79.3% of the predicted hypoglycemic events were avoided. Conclusions: The hypoglycemia avoidance rate was comparable to those in previous reports. In addition, we demonstrated that PLGM can markedly suppress severe hypoglycemia without deteriorating glycemic control in Japanese T1DM patients. It is necessary to further investigate the effective use of the PLGM feature such as establishing a lower limit and the timing of resumption.
AB - Aims/introduction: The predictive low glucose management (PLGM) system was introduced in March 2018 in Japan. Although there are some reports demonstrating the benefit of PLGM in preventing hypoglycemia, no data are currently available in Japanese patients with type 1 diabetes mellitus (T1DM). The aim of the present study is to evaluate the effect of PLGM with sensor-augmented pump therapy in the prevention of hypoglycemia in Japanese patients. Materials and methods: We included 16 patients with T1DM who used the MiniMed®640G system after switching from the MiniMed®620G system. We retrospectively analysed the data of the continuous glucose monitoring system in 1 month after switching to MiniMed®640G. Results: The area under the curve (AUC) of hypoglycemia of < 70 mg/dL was lowered from 0.42 ± 0.43 mg/dL day to 0.18 ± 0.18 mg/dL day (P = 0.012). Correspondingly, the duration of severe hypoglycemia (< 54 mg/dL) was reduced significantly from 15.3 ± 21.7 min/day to 4.8 ± 6.9 min/day (P = 0.019). The duration of hypoglycemia was reduced, but the reduction was not significant. Regarding the AUC for hyperglycemia > 180 mg/dL and the duration of hyperglycemia did not change. With the PLGM function, 79.3% of the predicted hypoglycemic events were avoided. Conclusions: The hypoglycemia avoidance rate was comparable to those in previous reports. In addition, we demonstrated that PLGM can markedly suppress severe hypoglycemia without deteriorating glycemic control in Japanese T1DM patients. It is necessary to further investigate the effective use of the PLGM feature such as establishing a lower limit and the timing of resumption.
KW - Hypoglycemia
KW - Predictive low glucose management (PLGM)
KW - Sensor-augmented pump therapy (SAP)
KW - Type 1 diabetes mellitus (T1DM)
UR - http://www.scopus.com/inward/record.url?scp=85073816358&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073816358&partnerID=8YFLogxK
U2 - 10.1007/s13340-019-00408-7
DO - 10.1007/s13340-019-00408-7
M3 - Article
AN - SCOPUS:85073816358
SN - 2190-1678
VL - 11
SP - 97
EP - 104
JO - Diabetology International
JF - Diabetology International
IS - 2
ER -